Banco Bilbao Vizcaya Argentaria S.A. Raises Stock Position in Zoetis Inc. $ZTS

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. increased its stake in Zoetis Inc. by 44.2% during the first quarter, reaching a total holding of 20,500 shares worth approximately $3.36 million.
• Zoetis reported a quarterly EPS of $1.76, beating analysts' expectations, with a year-over-year revenue increase of 4.2%.
• Insights from recent analysts' reports show a mixed sentiment, with some lowering their ratings while others maintain a positive outlook, leading to an average rating of "Moderate Buy" for Zoetis stock.

Banco Bilbao Vizcaya Argentaria S.A. increased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 44.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,500 shares of the company's stock after buying an additional 6,281 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Zoetis were worth $3,358,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Portside Wealth Group LLC increased its holdings in Zoetis by 24.7% in the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after purchasing an additional 6,672 shares in the last quarter. Tandem Investment Advisors Inc. increased its stake in shares of Zoetis by 100.3% in the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after buying an additional 198,089 shares during the period. Flagship Harbor Advisors LLC increased its stake in shares of Zoetis by 31.2% in the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock valued at $1,217,000 after buying an additional 1,760 shares during the period. Horizon Financial Services LLC acquired a new stake in shares of Zoetis in the first quarter valued at about $380,000. Finally, Sage Rhino Capital LLC grew its stake in Zoetis by 117.6% during the first quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock worth $1,155,000 after purchasing an additional 3,791 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler raised their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. UBS Group decreased their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Zoetis currently has a consensus rating of "Moderate Buy" and a consensus price target of $202.43.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.16% of the company's stock.

Zoetis Stock Up 0.5%

ZTS stock traded up $0.7080 during trading on Friday, reaching $156.3180. The stock had a trading volume of 2,426,297 shares, compared to its average volume of 3,450,163. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $69.28 billion, a price-to-earnings ratio of 26.91, a P/E/G ratio of 2.51 and a beta of 0.88. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company's 50 day moving average is $153.84 and its two-hundred day moving average is $158.52.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.